Rasburicase (Elitek) for Hyperuricemia
Rasburicase (Elitek - Sanofi-Synthelabo), a recombinant form of urate oxidase derived from the fungus Aspergillus flavus, has been approved by the FDA for intravenous (IV) management of hyperuricemia associated with tumor lysis syndrome in pediatric patients....
Cannot Access - We are sorry, but you cannot access the requested article.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
If you have already purchased this article, or have a subscription to The Medical Letter on Drugs and Therapeutics, please login or register to view it online.
Information about the article:
Title: Rasburicase (Elitek) for Hyperuricemia
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1143
Article Code: 1143b
Date: November 11, 2002
Volume: 44
Pages: 96-97
Publication: The Medical Letter on Drugs and Therapeutics
Issue #: 1143
Article Code: 1143b
Date: November 11, 2002
Volume: 44
Pages: 96-97
Subscribe to The Medical Letter on Drugs and Therapeutics for instant access to this article. Add this downloadable, electronic article to your cart (U.S. English version only)